To identify and understand the trends across various emerging concepts in cancer immunotherapy, we have leveraged substance data from CAS Content Collection and CAS Registry consisting of >204 million substances. Our analysis of >3.2 million substances sheds light on interesting trends -namely that protein/peptide sequences appear to be of greater commercial importance than small molecules as evidenced by the substantially higher proportion in patent publications. However, a more nuanced look at the protein/peptide sequence to small molecule ratio led to insights about substances classes currently being explored with respect to emerging targets. In addition, co-occurrences between selected emerging therapies and types of cancer display interesting overlaps indicating the use of targets across various cancer types.